{"_buckets": {"deposit": "f64153cd-7c84-4f60-8763-8c64333ce0f3"}, "_deposit": {"id": "27083", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "27083"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00027083"}, "item_10_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-11", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "11", "bibliographicPageEnd": "1030", "bibliographicPageStart": "1023", "bibliographicVolumeNumber": "23", "bibliographic_titles": [{"bibliographic_title": "Nephrology"}]}]}, "item_10_description_4": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "Aim: We aimed to evaluate the anti\u2010albuminuric effects of topiroxostat in Japanese hyperuricaemic patients with diabetic nephropathy. Methods: In this 24\u2010week, multicentre, open\u2010label, randomized (1 : 1) trial, we assigned hyperuricaemic patients with diabetic nephropathy (estimated glomerular filtration rate\u2009\u2265\u200920\u2009mL/min per 1.73m2) and overt proteinuria (0.3\u2009\u2264\u2009urine protein to creatinine ratio (UPCR) \u003c3.5\u2009g/g\u2009Cr) to either high dose (160\u2009mg daily) or low dose (40\u2009mg daily) topiroxostat. The primary endpoint was the change in albuminuria indicated by urine albumin\u2010to\u2010creatinine ratio (UACR) from the baseline at the final time point. Results: A total of 80 patients underwent randomization. The changes in UACR after 24\u2009weeks of treatment (or at the final time point if patients failed to reach 24\u2009weeks) relative to the baseline were \u2212122\u2009mg/gCr (95% CI: \u22125.1 to \u2212240.1, P\u2009=\u20090.041) in patients treated with high dose, while treatment with low dose topiroxostat could not show significant reduction (P\u2009=\u20090.067). In the linear mixed model including baseline albuminuria, eGFR, age, and sex as covariates, the decreases in UACR were still significant from baseline to 12\u2009weeks by 228.7\u2009\u00b1\u200983.2\u2009mg/gCr (P\u2009=\u20090.0075) in the high dose group. The adverse\u2010event profile during this study was not different between the groups. Conclusion: Topiroxostat 160\u2009mg daily reduced albuminuria in patients with diabetic nephropathy. (Funded by Sanwa Kagaku Kenkyusho; Trial registration, UMIN000015403). ", "subitem_description_type": "Abstract"}]}, "item_10_description_5": {"attribute_name": "\u5185\u5bb9\u8a18\u8ff0", "attribute_value_mlt": [{"subitem_description": "\u30d5\u30a1\u30a4\u30eb\u516c\u958b\uff1a2019-11-01", "subitem_description_type": "Other"}]}, "item_10_publisher_32": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "Wiley"}]}, "item_10_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1111/nep.13177", "subitem_relation_type_select": "DOI"}}]}, "item_10_rights_12": {"attribute_name": "\u6a29\u5229", "attribute_value_mlt": [{"subitem_rights": "\"This is the peer reviewed version of the following article: [Mizukoshi, T. , Kato, S. , Ando, M. , Sobajima, H. , Ohashi, N. , Naruse, T. , Saka, Y. , Shimizu, H. , Nagata, T. and Maruyama, S. (2018), Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial. Nephrology, 23: 1023-1030. doi:10.1111/nep.13177], which has been published in final form at [https://doi.org/10.1111/nep.13177]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.\""}]}, "item_10_select_15": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_10_source_id_61": {"attribute_name": "ISSN\uff08print\uff09", "attribute_value_mlt": [{"subitem_source_identifier": "1320-5358", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Mizukoshi, Toshihiro"}], "nameIdentifiers": [{"nameIdentifier": "88794", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kato, Sawako"}], "nameIdentifiers": [{"nameIdentifier": "88795", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ando, Masahiko"}], "nameIdentifiers": [{"nameIdentifier": "88796", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sobajima, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "88797", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohashi, Norimi"}], "nameIdentifiers": [{"nameIdentifier": "88798", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Naruse, Tomohiko"}], "nameIdentifiers": [{"nameIdentifier": "88799", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Saka, Yosuke"}], "nameIdentifiers": [{"nameIdentifier": "88800", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimizu, Hideaki"}], "nameIdentifiers": [{"nameIdentifier": "88801", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagata, Takanobu"}], "nameIdentifiers": [{"nameIdentifier": "88802", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Maruyama, Shoichi"}], "nameIdentifiers": [{"nameIdentifier": "88803", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-11-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "1_repositoryETUDE_Nephrology.pdf", "filesize": [{"value": "1.7 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1700000.0, "url": {"label": "1_repositoryETUDE_Nephrology", "url": "https://nagoya.repo.nii.ac.jp/record/27083/files/1_repositoryETUDE_Nephrology.pdf"}, "version_id": "fee2d56d-0b17-49a0-aef7-de207c641be4"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "albuminuria", "subitem_subject_scheme": "Other"}, {"subitem_subject": "diabetic nephropathy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "randomized study", "subitem_subject_scheme": "Other"}, {"subitem_subject": "topiroxostat", "subitem_subject_scheme": "Other"}, {"subitem_subject": "xanthine oxidoreductase inhibitor", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial"}]}, "item_type_id": "10", "owner": "1", "path": ["499/500/501"], "permalink_uri": "http://hdl.handle.net/2237/00029282", "pubdate": {"attribute_name": "\u516c\u958b\u65e5", "attribute_name_i18n": "\u516c\u958b\u65e5", "attribute_value": "2019-02-13"}, "publish_date": "2019-02-13", "publish_status": "0", "recid": "27083", "relation": {}, "relation_version_is_last": true, "title": ["Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial"], "weko_shared_id": null}